zurück

Brexucabtagene autoleucel (new indication: acute lymphoblastic leukemia, patients aged ≥ 26 years)

 

Subject:

  • Active Substance: Brexucabtagene autoleucel
  • Name: Tecartus®
  • Therapeutic area: Acute lymphoblastic leukemia
  • Pharmaceutical company: Gilead Sciences GmbH

 

Time table:

  • Start: 01.10.2022
  • Publication of assessment: 02.01.2023
  • End of public hearing: 23.01.2023
  • Final decision by G-BA: middle of March 2023

 

Comparative therapy:

  • No comparative therapy due to orphan drug designation